Search
BI 4060107
go.drugbank.com/drugs/DB33963ExperimentalBI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).
Sarracenia Purpurea
go.drugbank.com/drugs/DB13965ApprovedWithdrawn_Sarracenia purpurea_ attract and trap insects within their pitchers, or fused leaves, to consume nitrogen during the digestion process [A32509].
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Eribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic
Chlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalIt is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983] … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.
Aspartic acid
go.drugbank.com/drugs/DB00128ApprovedInvestigationalNutraceuticalOne of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
Tegoprazan
go.drugbank.com/drugs/DB16690InvestigationalTegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. … [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.
Ingenol mebutate
go.drugbank.com/drugs/DB05013ApprovedWithdrawnIngenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalIt is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects